BRKR * Stock Overview
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,372.36 |
| 52 Week High | US$1,372.36 |
| 52 Week Low | US$1,372.36 |
| Beta | 1.22 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 1.28% |
| 5 Year Change | n/a |
| Change since IPO | 50.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| BRKR * | MX Life Sciences | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how BRKR * performed against the MX Life Sciences industry.
Return vs Market: Insufficient data to determine how BRKR * performed against the MX Market.
Price Volatility
| BRKR * volatility | |
|---|---|
| BRKR * Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: BRKR * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BRKR *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 9,707 | Frank Laukien | www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
Bruker Corporation Fundamentals Summary
| BRKR * fundamental statistics | |
|---|---|
| Market cap | Mex$184.19b |
| Earnings (TTM) | Mex$6.72b |
| Revenue (TTM) | Mex$50.23b |
27.4x
P/E Ratio3.7x
P/S RatioIs BRKR * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRKR * income statement (TTM) | |
|---|---|
| Revenue | US$3.00b |
| Cost of Revenue | US$1.48b |
| Gross Profit | US$1.52b |
| Other Expenses | US$1.12b |
| Earnings | US$401.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.76 |
| Gross Margin | 50.61% |
| Net Profit Margin | 13.38% |
| Debt/Equity Ratio | 94.9% |
How did BRKR * perform over the long term?
See historical performance and comparison